(VIANEWS) – The NASDAQ ended the session with Exact Sciences jumping 11.04% to $78.84 on Wednesday, after five sequential sessions in a row of gains. NASDAQ jumped 1.04% to $12,306.44, following the last session’s downward trend on what was an all-around positive trend trading session today.
Exact Sciences’s last close was $71.00, 1.65% under its 52-week high of $72.19.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-3.66.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.39%.
Sales Growth
Exact Sciences’s sales growth is 11.7% for the current quarter and 8.5% for the next.
More news about Exact Sciences (EXAS).
